Stathis Kastritis, MD from the University of Athens School of Medicine, Athens, Greece discusses patients with Waldenström’s macroglobulinemia (WM) who require special attention at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. These patients present with hyperviscosity syndrome and need to be managed carefully; for example, plasmapheresis should be introduced before prescribing drugs like rituximab, which can further complicate the disease course. Dr Kastritis suggests that ibrutinib or proteasome inhibitors may be a good treatment for these patients. Another challenging patient is one with WM, who presents with neuropathy. This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.